Effects of SGLT-2 Inhibitors on Cardiac Function, Blood Glucose Levels, and Prognosis in Patients with Type 2 Diabetes Mellitus after Percutaneous Coronary Intervention: A Propensity Score Matching Study
DOI:
https://doi.org/10.59958/hsf.7519Keywords:
sodium–glucose cotransporter, percutaneous coronary intervention, type 2 diabetes mellitus, cardiac functionAbstract
Objective: To explore the effect of sodium–glucose cotransporter (SGLT-2) inhibitors on cardiac function, blood glucose level, and prognosis in patients with type 2 diabetes mellitus (T2DM) following percutaneous coronary intervention (PCI). Methods: A retrospective analysis was conducted on the clinical data of 195 patients with T2DM who underwent PCI in our hospital between September 2019 and August 2023. The patients were divided into control and observation groups on the basis of medical records. The general demographic information of all participants was collected. Propensity score matching (PSM) was employed to balance baseline data, allowing for the comparison of good cardiac function rates, cardiac function index levels, blood glucose levels, and adverse reactions after matching. Results: PSM matching was performed in a 1:1 ratio on the 84 patients enrolled in the two groups. The baseline data of the two groups were not statistically significantly different. Compared with those in the control group, the level of left ventricular ejection fraction had significantly increased and levels of left ventricular end-systolic diameter, glycosylated hemoglobin, fasting blood glucose, and 2 h postprandial blood glucose had significantly decreased in the observation group after treatment (p < 0.05). Left ventricular end-diastolic diameter and left ventricular posterior wall thickness (p > 0.05) showed no significant changes. The observation group had a higher rate of good cardiac function (95.24% vs. 80.95%) and lower total incidence of adverse reactions (11.90% vs. 30.95%) than the control group (p < 0.05). Conclusions: SGLT-2 inhibitors can significantly improve cardiac function and blood glucose levels in patients with T2DM after PCI with few adverse reactions and remarkable prognosis recovery effect. Therefore, they can be used in clinical practice.
References
Aswathi R, Viji D, Pricilla Charmine PS, Akram Husain RSR, Noorul Ameen SH, Ahmed SS, et al. Influence of KCNJ11 gene polymorphism in T2DM of south Indian population. Frontiers in Bioscience (Elite Edition). 2020; 12: 199–222.
Xiong S, Chen Q, Zhang Z, Chen Y, Hou J, Cui C, et al. A synergistic effect of the triglyceride-glucose index and the residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. Cardiovascular Diabetology. 2022; 21: 115.
Khamis AM. Pathophysiology, Diagnostic Criteria, and Approaches to Type 2 Diabetes Remission. Cureus. 2023; 15: e33908.
Jiang S, Mathias PC, Hendrix N, Shirts BH, Tarczy-Hornoch P, Veenstra D, et al. Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. The Pharmacogenomics Journal. 2022; 22: 188–197.
Tang L, Cui QW, Liu DP, Fu YY. The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention. Medicine. 2019; 98: e18312.
Wei J, Liu S, Wang X, Li B, Qiao L, Wang Y , et al. Efficacy and safety of shexiang baoxin pill for coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine. 2021; 2021.
Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. 2020; 142: 1713–1724.
Correale M, Mazzeo P, Mallardi A, Leopizzi A, Tricarico L, Fortunato M, et al. Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure. Cardiovascular Drugs and Therapy. 2022; 36: 1157–1164.
Shi G, Zhu N, Qiu L, Yan H, Zeng L, Wang D, et al. Impact of the 2020 China Diabetes Society Guideline on the Prevalence of Diabetes Mellitus and Eligibility for Antidiabetic Treatment in China. International Journal of General Medicine. 2021; 14: 6639–6645.
Fu Y, Cao Y, Wang H, Zhao J, Wang Z, Mo C, et al. Metabolic outcomes and renal function after simultaneous kidney/pancreas transplantation compared with kidney transplantation alone for type 2 diabetes mellitus patients. Transplant International. 2021; 34: 1198–1211.
Wu K, Wan M, Zhou H, Li C, Zhou X, Li E, et al. Mindfulness-based stress reduction combined with early cardiac rehabilitation improves negative mood states and cardiac function in patients with acute myocardial infarction assisted with an intra-aortic balloon pump: a randomized controlled trial. Frontiers in Cardiovascular Medicine. 2023; 10: 1166157.
Giroletti L, Brembilla V, Graniero A, Albano G, Villari N, Roscitano C, et al. Learning Curve Analysis of Robotic-Assisted Mitral Valve Repair with COVID-19 Exogenous Factor: A Single Center Experience. Medicina. 2023; 59: 1568.
Lee YJ, Wang CP, Hung WC, Tang WH, Chang YH, Hu DW, et al. Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020; 13: 1203–1214.
Wang H, Wang H, Wei Y, Li X, Jhummun V, Ahmed MA. Ten-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Patients with Type 2 Diabetes Mellitus Suffering from Left Main Coronary Disease: A Meta-Analysis. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders. 2021; 12: 1041–1054.
Lv Y, Zhao S. Diagnosis of Cardiac Rehabilitation after Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients by Emission Computed Tomography Image Features under Filtered Back Projection Reconstruction Algorithm. Journal of Healthcare Engineering. 2021; 2021: 6844549.
Shi FH, Li H, Shen L, Xu L, Ge H, Gu ZC, et al. Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function. The Journal of Clinical Endocrinology and Metabolism. 2022; 107: 1191–1203.
Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, et al. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacological Research. 2022; 180: 106243.
Carluccio E, Biagioli P, Reboldi G, Mengoni A, Lauciello R, Zuchi C, et al. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovascular Diabetology. 2023; 22: 235.
Vallianou NG, Tsilingiris D, Kounatidis D, Lempesis IG, Karampela I, Dalamaga M. Sodium glucose cotransporter 2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand? Polish Archives of Internal Medicine. 2022; 132: 16342.
Chan YH, Hsu TJ, Wang CL, Kao YW, Huang CY, Chu PH. Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function. ESC Heart Failure. 2020; 7: 2784–2796.
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure. 2021; 23: 1217–1225.
Maejima Y. SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function. Frontiers in Cardiovascular Medicine. 2020; 6: 186.
Hong AR, Koo BK, Kim SW, Yi KH, Moon MK. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice. Diabetes & Metabolism Journal. 2019; 43: 590–606.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, et al. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC. Cardiovascular Imaging. 2021; 14: 393–407.
Dugic A, Hagström H, Dahlman I, Rutkowski W, Daou D, Kulinski P, et al. Post-pancreatitis diabetes mellitus is common in chronic pancreatitis and is associated with adverse outcomes. United European Gastroenterology Journal. 2023; 11: 79–91.
Colosimo S, Mitra SK, Chaudhury T, Marchesini G. Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM. Diabetes Research and Clinical Practice. 2023; 206: 111016.
Forycka J, Hajdys J, Krzemińska J, Wilczopolski P, Wronka M, Młynarska E, et al. New Insights into the Use of Empagliflozin-A Comprehensive Review. Biomedicines. 2022; 10: 3294.
Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, et al. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity? Cardiovascular Drugs and Therapy. 2019; 33: 87–95.
Zeng Q, Zhou Q, Liu W, Wang Y, Xu X, Xu D. Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. Frontiers in Cardiovascular Medicine. 2021; 8: 636152.
